ArticleFrontiers in genetics2026
Metabolic signatures and diagnostic models of ischemic stroke and its hypertensive subtype: a non-targeted metabolomics and machine learning.
Article in Frontiers in genetics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Ischemic stroke (IS) is a leading cause of death and disability worldwide, yet reliable early diagnostic biomarkers remain lacking. This study employed non-targeted metabolomics and machine learning to characterize metabolic profiles and identify diagnostic biomarkers for IS. Methods: Non-targeted metabolomics profiling was performed using LC-MS/MS on plasma samples from 100 IS patients, including 50 cases of hypertensive ischemic stroke (HIS) and 50 cases of non-hypertensive ischemic stroke (NHIS), together with metabolomics data of 30 healthy controls (HC) from a previously published studies. Three machine learning algorithms, LASSO, glmBoost, and plsRglm, were used to screen candidate metabolite markers and construct a diagnostic model. Furthermore, targeted metabolomics was performed for quantitative validation of core differential metabolites in an independent clinical cohort. Results: A total of 59 significantly differential expressed metabolites (DEMs) between IS and HC were identified, mainly enriched in Ferroptosis, Glutathione metabolism, and Sphingolipid signaling pathways. L-Cystine, LPC 18:1, and LPC 14:0 were selected as candidate markers. The diagnostic model constructed based on these three metabolites achieved area under the curve (AUC) values of 0.901 (95% CI: 0.852-0.950) and 0.860 (95% CI: 0.798-0.879) in the training and validation sets, respectively. Targeted metabolomics validated the expression trends of these three metabolites, consistent with the untargeted findings. 50 DEMs were identified between HIS and NHIS, mainly involving amino acid biosynthesis, ether lipid metabolism, and glycerophospholipid metabolism. Indole metabolites were synergistically upregulated, and serum TNF-α levels were significantly increased in the HIS ( Conclusion: This study systematically delineated the metabolic reprogramming characteristics of IS, constructed diagnostic models for IS and HIS stroke with good diagnostic performance, and preliminarily validated the reliability of L-Cystine, LPC 18:1, and LPC 14:0 as candidate diagnostic markers, providing a scientific basis for the early diagnosis and precise intervention of IS.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.